What evidence was found regarding the effect of ACE inhibitors on mortality and graft loss in kidney transplant recipients?
The evidence review found that, compared to placebo or no treatment, ACEi had no significant effect on mortality, graft loss, or CV events (Supplementary Table S35,332,337 349 Supplementary Table S36,350 Supplementary Table S37,351 Supplementary Table S38352 ). With regard to ACEi there was trial evidence showing that these agents were effective at reducing BP and proteinuria in kidney transplant recipients (Supplementary Table S35). However, there was no significant effect of ACEi on all-cause mortality or graft loss, and their use was associated with a significant increase in adverse events in the kidney transplant population, including angioedema, cough, hyperkalemia, and anemia (Supplementary Table S35).